MedTrace Logo

Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App

NCT06675643 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-02-10

No results posted yet for this study

Summary

This study is being done to better understand patient experiences with using a mobile application, known as Vigilant, to monitor symptoms as outpatients and to gather preliminary data on the potential clinical benefit to remote monitoring of adverse events.

Conditions

Interventions

OTHER

Non-Interventional Study

Non-Interventional study

Sponsors & Collaborators

Principal Investigators

  • Svetomir N. Markovic, MD, PhD · Mayo Clinic

  • Lisa A. Kottschade, APRN, CNP · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-14
Primary Completion
2027-03-15
Completion
2027-03-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06675643 on ClinicalTrials.gov